p53 Mutations in non-small cell lung carcinomas in Hong Kong

Chest

Volumn 109, Issue 3, 1996, Pages 718-726

  Lung, Maria Li ^a   Wong, Maria P ^b   Skaanild, Mette T ^a   Fok, C L ^a   Lam, Wah Kit ^b   Yew, Wing Wai ^c  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

Hong Kong; lung carcinoma; p53

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER RISK; CANCER STAGING; DIAGNOSTIC VALUE; GENE MUTATION; HONG KONG; HUMAN; HUMAN TISSUE; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; POINT MUTATION; PRIORITY JOURNAL;

EID: 0011891330     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.3.718     Document Type: Article

References (38)

1. Soussi T, Legros Y, Lubin R, et al. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994; 57:1-9
2. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22:3551-55
3. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78
4. Bennett WP, Hollstein MC, Hau IC, et al. Mutational spectra and immunohistochemical analyses of p53 in human cancers. Chest 1992; 101:198-99
5. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991; 253:49-53
6. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351:453-56
7. Nigro MJ, Baker SJ, Presinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342:705-08
8. Bressac B, Kew M, Wanda J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350:429-31
9. Brash DE, Rudolf JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88:10124-28
10. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990's. Cancer Res 1991; 51(suppl):5023s-44s
11. Bennett WP, Colby TV, Travis WD, et al. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 1993; 53:4817-22
12. Iggo R, Gatter K, Barter J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-79
13. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 1992; 166:329-30
14. Dowell SP, Lane DP, Hall PA. The immunocytochemical detection of p53 protein in cytological specimens: technical considerations. Cytopathology 1994; 5:76-81
15. Dowell SP, Hall PA. The clinical relevance of the p53 tumour suppressor gene. Cytopathology 1994; 5:133-45
16. Weston A, Perrin LS, Forrester K, et al. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1992; 1:481-83
17. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246:491-94
18. Hensel CH, Xiang RH, Sakaguchi AY, et al. Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer. Oncogene 1991; 6:1067-71
19. Mitsudomi T, Steinberg SM, Nau MM, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7:171-80
20. Chiba I, Takahashi T, Nau MM, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990; 5:1603-10
21. Lehman TA, Bennett WP, Metcalf RA, et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991; 51:4090-96
22. D'Amico D, Carbone D, Mitsudomi T, et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992; 7:339-46
23. Marchetti A, Buttitta F, Merlo G, et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993; 53:2846-51
24. Takahashi T, Takahashi T, Suzuki H, et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991; 6:1775-78
25. Suzuki H, Takahashi T, Kuroishi T, et al. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992; 52:734-36
26. Noguchi M, Maezawa N, Nakanishi Y, et al. Application of the p53 gene mutation pattern for differential diagnosis of primary versus metastatic lung carcinomas. Diagn Mol Pathol 1993; 2:29-35
27. Lung ML, Wong M, Lam WK, et al. Incidence of ras oncogene activation in lung carcinomas in Hong Kong. Cancer 1992; 70: 760-63
28. Lee LN, Shew JY, Sheu JC, et al. Exon 8 mutation in p53 gene associated with nodal metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med 1994; 150:1667-71
29. Lam KY, Fu KH, Wong MP, et al. Significant changes in the distribution of histologic types of lung cancer in Hong Kong. Pathology 1993; 25:103-05
30. Parkin DM, Sankaranrayanan R. Overview on small cell lung cancer in the world: industrialized countries, third world, Eastern Europe. Anticancer Res 1994; 14:277-82
31. Casson AG, Mukhopadhyay T, Cleary KR, et al. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991; 51:4495-99
32. Mok, SCH, Lo KW, Tsao SW. Direct cycle sequencing of mutated alleles detected by PCR single-strand conformation polymorphism analysis. Biotechniques 1993; 14:790-93
33. Bodner SM, Minna JD, Jensen SM, et al. p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7:743-49
34. Westra WH, Offerhaus JA, Goodman SN, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993; 17:213-20
35. Oliner JD, Peteupol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-60
36. Price BD, Park SJ. DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res 1994; 54: 896-99
37. Reifenberger G, Liu L, Ichinnura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53:2736-39
38. Takahashi T, D'Amico D, Chiba I, et al. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J Clin Invest 1990; 86:363-69